US · Healthcare · Healthcare Plans
EPS came in at 6.99 against a street estimate of 4.66 — a beat of 50.0%.
Analysts rate Elevance Health Inc a buy (14 buy, 8 hold, 0 sell out of 22) with an average price target of $482.38.
CONFIDENT Elevance raised 2026 adjusted EPS guidance to at least $29 and expects at least 12% adjusted EPS growth in 2027, supported by Medicaid improvement, Medicare execution and Carelon expansion. Q3 FY26 No geographic regional performance detail was provided. Analysts focused heavily on Medicaid margin recovery, work requirements, Commercial pricing and Carelon growth. Management emphasized improving rates plus controllable medical-cost actions, while acknowledging implementation uncertainty. 2026-10-21…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 8.76% |
| Vanguard Capital Management, LLC | 6.48% |
| State Street Corp | 4.81% |
| Wellington Management Company LLP | 4.25% |
| Arnhold & S. Bleichroeder Advisers, LLC | 3.86% |
| Vanguard Portfolio Management, LLC | 2.87% |
| Sanders Capital, LLC | 2.69% |
| Geode Capital Management, LLC | 2.38% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Third-quarter 2026 total revenues were $51,429 million, up from $50,711 million in the third quarter of 2025. • Third-quarter sha | 2026-10-21 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 operating revenue was $50.4 billion, up 0.7% from $50.1 billion in 3Q 2025. • Diluted EPS was $6.27, up 17.9% | 2026-10-21 |
| Reg FD disclosure · Q3 2026 ELEVANCE HEALTH, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Full year 2026 shareholders' earnings guidance: at least $20.10 per diluted share (inclu | 2026-09-10 |
| Quarterly report · Q2 2026 ELEVANCE HEALTH, INC. – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues for six months ended June 30, 2026: $100,655 million (vs. $98,667 mil | 2026-07-15 |
| Results announced · Q3 2026 ELEVANCE HEALTH Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 operating revenue: $49.8 billion, up 0.8% year-over-year from $49.4 billion in Q | 2026-07-15 |
| Reg FD disclosure · Q2 2026 ELEVANCE HEALTH, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Full year 2026 shareholders' earnings guidance: at least $19.85 per diluted share (inclu | 2026-06-10 |
| Shareholder vote results · Q2 2026 ELEVANCE HEALTH, INC. – SHAREHOLDER MEETING SUMMARY (MAY 13, 2026) HEADLINE NUMBERS • Annual Meeting held May 13, 2026 with 194,441,339 shares repre | 2026-05-13 |
| Quarterly report · Q1 2026 ELEVANCE HEALTH, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues: $50.181 billion (Q1 2026) vs. $48.891 billion (Q1 2025) — up 2.6% • | 2026-04-22 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.72 / share ex-date Dec 4, 2026 · pay Dec 18, 2026 | 2026-12-04 |
| Dividend | $1.72 / share ex-date Sep 10, 2026 · pay Sep 25, 2026 | 2026-09-10 |
| Dividend | $1.72 / share ex-date Jun 10, 2026 · pay Jun 25, 2026 | 2026-06-10 |
| Dividend | $1.72 / share ex-date Mar 10, 2026 · pay Mar 25, 2026 | 2026-03-10 |
| Dividend | $1.71 / share ex-date Dec 5, 2025 · pay Dec 19, 2025 | 2025-12-05 |
| Announcement | Date |
|---|---|
| Reaffirms 2026 adjusted EPS guidance of at least $25.50 per share Elevance Health (ELV), a major health insurance company, reported that the Centers for Medicare & Medicaid Services (CMS) intends to impose sanctions on the company effective March 31, 2026. | 2026-03-10 |
| Reaffirms full year 2026 earnings per share and benefit expense ratio guidance Elevance Health announced that Peter D. Haytaian is stepping down as Executive Vice President and President of Carelon effective May 4, 2026, to focus on family commitments. He will continue | 2026-02-26 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Elevance Health Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.